Total Payments
$732.37
2022 Payments
$36.59
Companies
5
Transactions
58
Medicare Patients
4,962
Medicare Billing
$305,205
Payment Breakdown by Category
Food & Beverage$720.21 (98.3%)
Education$12.16 (1.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $720.21 | 57 | 98.3% |
| Education | $12.16 | 1 | 1.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | $517.30 | 50 | $0 (2019) |
| Amgen Inc. | $136.11 | 3 | $0 (2019) |
| Teva Pharmaceuticals USA, Inc. | $42.37 | 3 | $0 (2019) |
| Biohaven Pharmaceutical Holding Company Ltd. | $24.43 | 1 | $0 (2022) |
| IMPEL PHARMACEUTICALS INC. | $12.16 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $36.59 | 2 | Biohaven Pharmaceutical Holding Company Ltd. ($24.43) |
| 2019 | $95.29 | 7 | Teva Pharmaceuticals USA, Inc. ($42.37) |
| 2018 | $394.39 | 32 | Supernus Pharmaceuticals, Inc. ($288.26) |
| 2017 | $206.10 | 17 | Supernus Pharmaceuticals, Inc. ($206.10) |
All Payment Transactions
58 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/23/2022 | Biohaven Pharmaceutical Holding Company Ltd. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $24.43 | General |
| Category: PRIMARY CARE | ||||||
| 04/14/2022 | IMPEL PHARMACEUTICALS INC. | Trudhesa (Drug) | Education | In-kind items and services | $12.16 | General |
| Category: Migraine | ||||||
| 08/15/2019 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $11.71 | General |
| Category: AED | ||||||
| 07/22/2019 | Teva Pharmaceuticals USA, Inc. | AJOVY (Drug) | Food and Beverage | In-kind items and services | $13.10 | General |
| Category: Central Nervous System | ||||||
| 06/26/2019 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $11.23 | General |
| Category: AED | ||||||
| 06/20/2019 | Teva Pharmaceuticals USA, Inc. | AJOVY (Drug) | Food and Beverage | In-kind items and services | $15.35 | General |
| Category: Central Nervous System | ||||||
| 05/24/2019 | Amgen Inc. | Aimovig (Biological) | Food and Beverage | In-kind items and services | $14.66 | General |
| Category: Neuroscience | ||||||
| 05/14/2019 | Teva Pharmaceuticals USA, Inc. | AJOVY (Drug) | Food and Beverage | In-kind items and services | $13.92 | General |
| Category: Central Nervous System | ||||||
| 01/11/2019 | Amgen Inc. | Aimovig (Biological) | Food and Beverage | In-kind items and services | $15.32 | General |
| Category: Neuroscience | ||||||
| 12/12/2018 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $3.67 | General |
| Category: AED | ||||||
| 12/06/2018 | Amgen Inc. | Aimovig (Biological) | Food and Beverage | In-kind items and services | $106.13 | General |
| Category: Neuroscience | ||||||
| 11/21/2018 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $7.95 | General |
| Category: AED | ||||||
| 10/23/2018 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $8.82 | General |
| Category: AED | ||||||
| 10/04/2018 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $10.36 | General |
| Category: AED | ||||||
| 09/27/2018 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $6.89 | General |
| Category: AED | ||||||
| 09/21/2018 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $17.03 | General |
| Category: AED | ||||||
| 09/10/2018 | Supernus Pharmaceuticals, Inc. | OXTELLAR XR (Drug) | Food and Beverage | Cash or cash equivalent | $5.57 | General |
| Category: AED | ||||||
| 09/04/2018 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $9.63 | General |
| Category: AED | ||||||
| 08/29/2018 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $7.87 | General |
| Category: AED | ||||||
| 08/13/2018 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $8.18 | General |
| Category: AED | ||||||
| 08/10/2018 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $12.14 | General |
| Category: AED | ||||||
| 08/06/2018 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $12.43 | General |
| Category: AED | ||||||
| 08/02/2018 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $6.04 | General |
| Category: AED | ||||||
| 07/30/2018 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $13.35 | General |
| Category: AED | ||||||
| 07/17/2018 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $14.57 | General |
| Category: AED | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 915 | 1,524 | $361,399 | $68,463 |
| 2022 | 15 | 1,343 | 1,988 | $596,797 | $85,427 |
| 2021 | 16 | 1,437 | 2,050 | $608,804 | $87,625 |
| 2020 | 16 | 1,267 | 1,594 | $518,326 | $63,691 |
Total Patients
4,962
Total Services
7,156
Medicare Billing
$305,205
Procedure Codes
63
All Medicare Procedures & Services
63 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 105 | 105 | $27,195 | $13,185 | 48.5% |
| 92546 | Test for abnormal eye movement using a rotating chair | Office | 2023 | 88 | 88 | $99,000 | $8,564 | 8.7% |
| 97112 | Therapy procedure to re-educate brain-to-nerve-to-muscle function, each 15 minutes | Office | 2023 | 86 | 361 | $38,054 | $8,488 | 22.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 37 | 37 | $11,840 | $6,202 | 52.4% |
| 97110 | Therapy procedure using exercise to develop strength, endurance, range of motion, and flexibility, each 15 minutes | Office | 2023 | 62 | 284 | $28,963 | $5,010 | 17.3% |
| 95992 | Repositioning exercises of head for treatment of dizziness, each day | Office | 2023 | 56 | 144 | $9,399 | $4,806 | 51.1% |
| 97162 | Evaluation for physical therapy, typically 30 minutes | Office | 2023 | 62 | 62 | $15,538 | $4,615 | 29.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 27 | 32 | $5,920 | $3,003 | 50.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 36 | 43 | $5,805 | $2,711 | 46.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 32 | 32 | $5,440 | $2,545 | 46.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 18 | 18 | $4,032 | $2,533 | 62.8% |
| 97164 | Re-evaluation for physical therapy, typically 20 minutes | Office | 2023 | 24 | 36 | $5,993 | $1,959 | 32.7% |
| 92541 | Test for abnormal eye movement with recording | Office | 2023 | 88 | 88 | $9,680 | $1,784 | 18.4% |
| 92544 | Test for abnormal eye movement using a moving target with recording | Office | 2023 | 87 | 87 | $82,650 | $1,245 | 1.5% |
| 92545 | Test for abnormal eye movement using a moving target that moves back and forth with recording | Office | 2023 | 88 | 88 | $10,560 | $1,188 | 11.3% |
| 92537 | Test to assess balance during warm and cool irrigation in both ears | Office | 2023 | 19 | 19 | $1,330 | $624.72 | 47.0% |
| 92546 | Test for abnormal eye movement using a rotating chair | Office | 2022 | 188 | 188 | $211,500 | $19,153 | 9.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 119 | 119 | $30,821 | $15,043 | 48.8% |
| 97112 | Therapy procedure to re-educate brain-to-nerve-to-muscle function, each 15 minutes | Office | 2022 | 109 | 418 | $43,663 | $9,991 | 22.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 35 | 35 | $11,200 | $6,144 | 54.9% |
| 97110 | Therapy procedure using exercise to develop strength, endurance, range of motion, and flexibility, each 15 minutes | Office | 2022 | 78 | 327 | $32,530 | $6,012 | 18.5% |
| 97162 | Evaluation for physical therapy, typically 30 minutes | Office | 2022 | 69 | 69 | $17,163 | $5,498 | 32.0% |
| 95992 | Repositioning exercises of head for treatment of dizziness, each day | Office | 2022 | 56 | 131 | $8,524 | $4,572 | 53.6% |
| 92541 | Test for abnormal eye movement with recording | Office | 2022 | 188 | 188 | $20,680 | $3,914 | 18.9% |
| 92544 | Test for abnormal eye movement using a moving target with recording | Office | 2022 | 188 | 188 | $178,600 | $2,767 | 1.5% |
About Melissa Ramocki, M.D., PH. D
Melissa Ramocki, M.D., PH. D is a Neurology healthcare provider based in E Greenwich, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/16/2008. The National Provider Identifier (NPI) number assigned to this provider is 1821255035.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Melissa Ramocki, M.D., PH. D has received a total of $732.37 in payments from pharmaceutical and medical device companies, with $36.59 received in 2022. These payments were reported across 58 transactions from 5 companies. The most common payment nature is "Food and Beverage" ($720.21).
As a Medicare-enrolled provider, Ramocki has provided services to 4,962 Medicare beneficiaries, totaling 7,156 services with total Medicare billing of $305,205. Data is available for 4 years (2020–2023), covering 63 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location E Greenwich, RI
- Active Since 05/16/2008
- Last Updated 07/07/2014
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1821255035
Products in Payments
- TROKENDI XR (Drug) $493.25
- Aimovig (Biological) $136.11
- AJOVY (Drug) $42.37
- NURTEC ODT (Drug) $24.43
- OXTELLAR XR (Drug) $24.05
- Trudhesa (Drug) $12.16
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.